Relationship between colorectal cancer biomarkers and response to epidermal growth factor receptor monoclonal antibodies

Journal of Clinical Oncology

Volumn 28, Issue 28, 2010, Pages

  Hawkes, Eliza ^a   Cunningham, David ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR MONOCLONAL ANTIBODY; IRINOTECAN; K RAS PROTEIN; OXALIPLATIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PIK3CA PROTEIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BRAF PROTEIN, HUMAN; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; KRAS PROTEIN, HUMAN; MONOCLONAL ANTIBODY; ONCOPROTEIN; PIK3CA PROTEIN, HUMAN; PTEN PROTEIN, HUMAN; RAS PROTEIN; TUMOR MARKER;

CANCER STAGING; CANCER SURVIVAL; COLORECTAL CANCER; DRUG SENSITIVITY; GENE EXPRESSION PROFILING; GENE MUTATION; GENETIC MARKER; GENETIC VARIABILITY; HUMAN; IMMUNOHISTOCHEMISTRY; LETTER; LOSS OF FUNCTION MUTATION; MICROSATELLITE INSTABILITY; ONCOGENE N RAS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RELAPSE FREE SURVIVAL; TREATMENT RESPONSE; CLINICAL TRIAL; COLORECTAL TUMOR; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; MUTATION; NOTE; ONCOGENE RAS; TREATMENT OUTCOME;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, RAS; HUMANS; MUTATION; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; PTEN PHOSPHOHYDROLASE; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 78049443211     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.29.5626     Document Type: Letter

References (28)

1. Laurent-Puig P, Cayre A, Manceau G, et al: Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol 27:5924-5930, 2009
2. Richman SD, Seymour MT, Chambers P, et al: KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: Results from the MRC FOCUS trial. J Clin Oncol 27:5931-5937, 2009
3. Bardelli A, Siena S: Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol 28:1254-1261, 2010
4. Di Nicolantonio F, Martini M, Molinari F, et al: Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 26:5705-5712, 2008
5. Wong R, Cunningham D: Using predictive biomarkers to select patients with advanced colorectal cancer for treatment with epidermal growth factor receptor antibodies. J Clin Oncol 26:5668-5670, 2008
6. Linardou H, Dahabreh IJ, Kanaloupiti D, et al: Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: A systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol 9:962-972, 2008
7. Lambrechts D, De Roock W, Prenen H, et al: The role of KRAS, BRAF, NRAS, and PIK3CA mutations as markers of resistance to cetuximab in chemorefractory metastatic colorectal cancer. J Clin Oncol 27:173s, 2009 (suppl; abstr 4020)
8. De Roock W, Claes B, Fountzilas G, et al: PIK3CA, BRAF and KRAS mutations and outcome prediction in chemorefractory metastatic colorectal cancer (mCRC) patients treated with EGFR targeting monoclonal antibodies (MoAbs): Results of a European Consortium. Eur J Cancer 7:302s, 2009 (abstr 6005)
9. Tol J, Nagtegaal ID, Punt CJ: BRAF mutation in metastatic colorectal cancer. N Engl J Med 361:98-99, 2009
10. Ogino S, Nosho K, Kirkner GJ, et al: CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut 58:90-96, 2009
11. Roth A, Klingbiel D, Yan P, et al: Molecular and clinical determinants of survival following relapse after curative treatment of stage II-III colon cancer (CC): Results of the translational study on the PETACC 3-EORTC 40993-SAKK 60-00 trial. J Clin Oncol 28:261s, 2010 (suppl; abstr 3504)
12. Bokemeyer C, Kohne C, Rougier P, et al: Cetuximab with chemotherapy (CT) as first-line treatment for metastatic colorectal cancer (mCRC): Analysis of the CRYSTAL and OPUS studies according to KRAS and BRAF mutation status. J Clin Oncol 28:262s, 2010 (suppl; abstr 3506)
13. Maughan T, Adams RA, Smith CG, et al: Addition of cetuximab to oxaliplatin-based combination chemotherapy (CT) in patients with KRAS wild-type advanced colorectal cancer (ACRC): A randomised superiority trial (MRC COIN). Eur J Cancer 7:6LBA, 2009 (abstr)
14. Goel A, Arnold CN, Niedzwiecki D, et al: Frequent inactivation of PTEN by promoter hypermethylation in microsatellite instability-high sporadic colorectal cancers. Cancer Res 64:3014-3021, 2004 (Pubitemid 38581399)
15. Meng F, Henson R, Wehbe-Janek H, et al: MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 133:647-658, 2007 (Pubitemid 47187346)
16. Frattini M, Saletti P, Romagnani E, et al: PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer 97:1139-1145, 2007 (Pubitemid 47587019)
17. Razis E, Briasoulis E, Kostopoulos I, et al: Predictive markers for the treatment of colorectal cancer with cetuximab. J Clin Oncol 24:616s, 2006 (suppl 18S; abstr 13500)
18. Negri FV, Bozzetti C, Lagrasta CA, et al: PTEN status in advanced colorectal cancer treated with cetuximab. Br J Cancer 102:162-164, 2010
19. Sircar K, Yoshimoto M, Monzon FA, et al: PTEN genomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancer. J Pathol 218:505-513, 2009
20. Loupakis F, Pollina L, Stasi I, et al: PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J Clin Oncol 27:2622-2629, 2009
21. Kate K, Yamada Y, Ite Y, et al: Efficacy of cetuximab against KRAS wild type colorectal cancer with BRAF or PIK3CA mutations. Presented at 2010 Gastrointestinal Cancers Symposium, Orlando, FL, January 22-24, 2010 (abstr 393)
22. Linot B, Capitain O, Metges J, et al: Impact of PI3K, BRAF and KRAS mutations on efficacy intensified FOLFIRI + cetuximab regimen in advanced colorectal cancer. Presented at 2010 Gastrointestinal Cancers Symposium, Orlando, FL, January 22-24, 2010 (abstr 365)
23. Ogino S, Nosho K, Kirkner GJ, et al: PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer. J Clin Oncol 27:1477-1484, 2009
24. Prenen H, De Schutter J, Jacobs B, et al: PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer. Clin Cancer Res 15:3184-3188, 2009
25. Sartore-Bianchi A, Martini M, Molinari F, et al: PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res 69:1851-1857, 2009
26. Perrone F, Lampis A, Orsenigo M, et al: PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. Ann Oncol 20:84-90, 2009
27. Khambata-Ford S, Garrett CR, Meropol NJ, et al: Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 25:3230-3237, 2007 (Pubitemid 47325606)
28. Jacobs B, De Roock W, Piessevaux H, et al: Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab. J Clin Oncol 27:5068-5074, 2009